Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …

Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway
which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian …

Inhibition of Bruton's tyrosine kinase (BTK) has revolutionized the treatment landscape for
patients with chronic lymphocytic leukemia (CLL). By targeting this critical kinase in proximal …

Starting with the first-in-class agent ibrutinib, the development of Bruton tyrosine kinase
(BTK) inhibitors has led to dramatic improvements in the management of B-cell …

Tirabrutinib (Velexbru®) is an orally administered, small molecule, Bruton's tyrosine kinase
(BTK) inhibitor being developed by Ono Pharmaceutical and its licensee Gilead Sciences for …

Phosphatidylinositol 3-kinase (PI3K) inhibitors are effective in chronic lymphocytic leukemia
(CLL). However, the severe toxicity profile associated with the first-generation inhibitors …

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western
countries and is characterized by the clonal expansion of mature CD5+ B cells. There have …

Simple Summary Chronic lymphocytic leukemia (CLL) treatment scenario is rapidly
evolving. As a consequence of longer observation, despite remarkable clinical results …